MEI Pharma (MEIP) and Kyowa Kirin Report Clinical Data on Zandelisib
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- Lucid Group shares quickly cut in half on report of potential bankruptcy
- HSBC Downgrades IBM (IBM) to Reduce, 'Stretched Valuation'
MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology Association 2022 Hybrid Congress
June 10, 2022 3:00 AM EDTZandelisib Demonstrated 70.3% Objective Response Rate and 35.2% Complete Response Rate
87.5% of Responses Achieved in First Two Cycles of Therapy, 75% of Complete Responses in first four cycles
9.9% of Patients Discontinued Therapy Due to a Drug Related Adverse Event
Primarily, Grade 3 AESIs to Date Occurred in Cycles 1-3.
SAN DIEGO & TOKYO--(BUSINESS WIRE)-- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty... More
